Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927153 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29644745 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18511052 | 1.00 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18822706 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24499270 | 0.94 | TYMP (0.39) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29581997 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26535891 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24878603 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL668595 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25873876 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694867-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025103453-A1 | SIRNA FOR INHIBITING ANGIOTENSINOGEN EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| EP-3801561-B1 | METHODS FOR THE TREATMENT OF BLADDER CANCER | EISAI R&D MAN CO LTD (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-20240318174-A1 | Multi-Valent Oligonucleotide Agent and Methods of Use Thereof | RACTIGEN THERAPEUTICS (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-111032672-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3762397-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11945834-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-110461416-B | Cyclic dinucleotide compounds for the treatment of cancer | 卫材 R&D 管理有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4234567-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | ST Pharm Co., Ltd. (KR) | 2023-08-30 | — | — | EP | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| EP-3676278-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4008403-A1 | CYCLIC DI-NUCLEOTIDES COMPOUNDS FOR THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339188-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945834-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, NTPCR | TYMP 6/4885PRMT6 1351/4885PRKAG1 332/4885 |
| US-11339188-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | TYMP 281/4885PRMT6 1399/4885PRKAG1 2643/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 1508/4885PRMT6 3865/4885PRKAG1 435/4885 |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | TYMP 6/4885PRMT6 1514/4885PRKAG1 596/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | TYMP 5/4885PRMT6 1652/4885PRKAG1 503/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | TYMP 5/4885PRMT6 1652/4885PRKAG1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.